Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL
W.-H. Liu, P. Mrozek-Gorska, T. Herold, L. Schwarzkopf, D. Pich, K. Völse, A.-K. Wirth, M. C. Melo-Narvaez, M. Carlet, W. Hammerschmidt, I. Jeremias
The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.
bioRxiv · Mar 6, 2020Cancer Biology